|
Type of Study | No. of patients | Treatment | Detection Method | Outcome | Author |
|
Neoadjuvant | 21 patients | 5-fluorouracil, epirubicin, cyclophosphamide and paclitaxel | RT-PCR | Differences seen in expression before treatment, no difference in expression response to treatment | [46] |
Neoadjuvant | 50 | Cyclophosphamide, doxorubicin and 5-fluorouracil | Immunohistochemistry | Significant correlation between PGP expression prior to treatment and clinical response | [53] |
Adjuvant | 171 | Chemotherapy +/− radiotherapy +/− hormonal therapy | RT-PCR | No significant correlation between PGP and MRP1 expression and survival | [48] |
Adjuvant | 85 | Anthracycline based | RT-PCR | No significant influence of PGP or MRP1 expression on survival | [49] |
Adjuvant | 38 | Doxorubicin | RT-PCR | No correlation between MRP1 expression and survival | [50] |
Adjuvant | 27 | Chemoendocrine | RT-PCR | High expression levels of MRP1 increased risk of relapse. No significant difference in PGP expression | [54] |
Adjuvant | 1034 | Cyclophosphamide, methotrexate and 5-fluorouracil or tamoxifen and goserelin | Immunohistochemistry | MRP1 expression predicts a shorter survival in patients treated with conventional chemotherapy | [55] |
Adjuvant | 59 | Cyclophosphamide, methotrexate and 5-fluorouracil or 5-fluorouracil, doxorubicin/epirubicin and cyclophosphamide | RT-PCR | High PGP expression significant predictor of poor prognosis | [51] |
Adjuvant | 259 | Cyclophosphamide, methotrexate and 5-fluorouracil | Immunohistochemistry | Increased expression of MRP1 associated with increase in relapse and number of deaths | [56] |
Adjuvant | 104 | Radiotherapy +/− chemotherapy +/− hormonal therapy | Immunohistochemistry | High expression levels of PGP associated with shorter survival | [57] |
|